 BMEZs portfolio has a combination of unknown small-cap next generation healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite the fund being non-diversified. 